Protara Therapeutics, Inc.

Protara Therapeutics, Inc. (Nasdaq: TARA) is a clinical-stage biopharmaceutical company based in New York City focused on advancing transformative therapies for cancer and rare diseases. The company applies modern scientific, regulatory, and manufacturing advancements to established mechanisms to create efficient, de-risked clinical programs with the goal of bringing life-changing therapies to patients with limited treatment options.

Protara's pipeline centers on two primary development programs. TARA-002 is an investigational cell therapy derived from the same master cell bank of genetically distinct group A Streptococcus pyogenes as OK-432, a broad immunopotentiator approved in Japan and Taiwan for lymphatic malformations and multiple oncologic indications. The company has secured worldwide rights to TARA-002 excluding Japan and Taiwan. TARA-002 is currently in clinical development for non-muscle invasive bladder cancer (NMIBC), representing approximately eighty percent of bladder cancer diagnoses with roughly sixty-five thousand annual U.S. diagnoses, and for lymphatic malformations (LMs), rare non-malignant cysts of the lymphatic vascular system primarily affecting children. The company's second program, IV Choline Chloride, is an investigational phospholipid substrate replacement therapy for patients receiving parenteral support, which includes both nutrition and fluids. Approximately ninety thousand people in the U.S. require parenteral support annually, with roughly thirty thousand on long-term support.

Neither product candidate has received FDA approval. The company has never generated revenues from product sales and does not expect to generate revenues in the near term. Protara has received several regulatory designations supporting its development programs, including Orphan Drug Designation and Fast Track Designation for IV Choline Chloride, and Breakthrough Therapy Designation and Fast Track Designation for TARA-002 in lymphatic malformations. The company manufactures TARA-002 through a contract development and manufacturing organization at a current Good Manufacturing Practices-compliant facility in the United States and produces IV Choline Chloride end-to-end domestically through a similar arrangement. Protara's strategy emphasizes building operational capabilities to successfully commercialize its oncology and rare disease programs as it approaches potential regulatory filings and approvals.